S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
S&P 500   4,274.21 (+0.02%)
DOW   33,556.50 (-0.19%)
QQQ   353.22 (-0.28%)
AAPL   170.31 (-0.96%)
MSFT   311.99 (-0.05%)
META   293.06 (-1.97%)
GOOGL   129.66 (+0.85%)
AMZN   125.64 (-0.27%)
TSLA   238.57 (-2.27%)
NVDA   422.45 (+0.80%)
NIO   8.45 (+0.48%)
BABA   85.90 (-0.01%)
AMD   97.74 (+1.85%)
T   14.88 (-0.93%)
F   12.34 (-0.72%)
MU   67.75 (-0.28%)
CGC   0.90 (-2.07%)
GE   110.61 (+0.62%)
DIS   79.69 (-0.45%)
AMC   7.60 (-3.92%)
PFE   32.20 (-0.62%)
PYPL   57.07 (-3.16%)
NFLX   378.63 (-0.16%)
Positive News SentimentPositive News
NASDAQ:ALGS

Aligos Therapeutics (ALGS) Stock Forecast, Price & News

$0.71
-0.02 (-2.74%)
(As of 02:27 PM ET)
Compare
Today's Range
$0.70
▼
$0.76
50-Day Range
$0.73
▼
$1.00
52-Week Range
$0.70
▼
$2.41
Volume
16,978 shs
Average Volume
223,990 shs
Market Capitalization
$30.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability

Aligos Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
440.5% Upside
$4.00 Price Target
Short Interest
Bearish
2.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
1.57mentions of Aligos Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.83) to ($1.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

178th out of 963 stocks

Biological Products, Except Diagnostic Industry

25th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

ALGS stock logo

About Aligos Therapeutics (NASDAQ:ALGS) Stock

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

ALGS Price History

ALGS Stock News Headlines

September 21, 2023 | finance.yahoo.com
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
August 20, 2023 | fool.com
Aligos Therapeutics (NASDAQ: ALGS)
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 3, 2023 | msn.com
Aligos Therapeutics GAAP EPS of -$0.43 beats by $0.06, revenue of $2.59M
August 3, 2023 | finance.yahoo.com
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
August 3, 2023 | finance.yahoo.com
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
July 28, 2023 | finance.yahoo.com
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
July 19, 2023 | finance.yahoo.com
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
June 21, 2023 | finance.yahoo.com
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 7, 2023 | it.tmcnet.com
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
May 24, 2023 | finance.yahoo.com
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
May 15, 2023 | msn.com
Aligos Therapeutics and Xiamen Amoytop Biotech join hands for the treatment of liver diseases
May 12, 2023 | finance.yahoo.com
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
May 5, 2023 | markets.businessinsider.com
SVB Securities Remains a Hold on Aligos Therapeutics (ALGS)
May 5, 2023 | finance.yahoo.com
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
May 4, 2023 | msn.com
Recap: Aligos Therapeutics Q1 Earnings
May 4, 2023 | benzinga.com
Aligos Therapeutics Stock (NASDAQ:ALGS), Dividends
April 27, 2023 | finance.yahoo.com
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
April 17, 2023 | finance.yahoo.com
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 30% Dip In Price Shows Sentiment Is Matching Revenues
April 11, 2023 | tmcnet.com
Aligos Therapeutics to Present Data from Chronic Hepatitis
April 11, 2023 | finance.yahoo.com
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
March 29, 2023 | finance.yahoo.com
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
March 14, 2023 | msn.com
Aligos Therapeutics Earnings Perspective: Return On Capital Employed
March 9, 2023 | finance.yahoo.com
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
March 9, 2023 | finance.yahoo.com
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
March 9, 2023 | finance.yahoo.com
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
See More Headlines
Receive ALGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALGS Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALGS
CUSIP
N/A
CIK
1799448
Web
www.aligos.com
Phone
800-466-6059
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+447.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-96,050,000.00
Net Margins
-476.77%
Pretax Margin
-472.13%
Return on Equity
-86.51%
Return on Assets
-61.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.46
Quick Ratio
3.46

Sales & Book Value

Annual Sales
$13.91 million
Price / Sales
2.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.42 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
43,500,000
Free Float
36,325,000
Market Cap
$31.76 million
Optionable
Not Optionable
Beta
2.19
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 61)
    Ph.D., CEO & Chairman
    Comp: $832.73k
  • Dr. Leonid Beigelman Ph.D. (Age 64)
    Pres & Director
    Comp: $664.43k
  • Dr. Julian A. Symons DPHIL (Age 62)
    Exec. VP & Chief Scientific Officer
    Comp: $618.66k
  • Ms. Lesley Ann Calhoun CPA (Age 57)
    Exec. VP & CFO
  • Ms. Lucinda Y. Quan J.D. (Age 51)
    Exec. VP, Chief Bus. Officer & Gen. Counsel
  • Kristina Engeseth
    VP and Head of People & Culture
  • Dr. Matthew W. McClure M.D. (Age 51)
    Exec. VP & Chief Medical Officer
  • Dr. Sushmita M. Chanda DABT (Age 57)
    Ph.D., Exec. VP of Translational Safety Sciences
  • Dr. David B. Smith Ph.D.
    Exec. VP & Head of Chemical Operations
  • Dr. Tse-I Lin Ph.D.
    VP of Early Compound Devel. & Belgian Site Head

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ALGS Stock - Frequently Asked Questions

Should I buy or sell Aligos Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aligos Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALGS shares.
View ALGS analyst ratings or view top-rated stocks.

What is Aligos Therapeutics' stock price forecast for 2023?

3 Wall Street research analysts have issued 12-month price targets for Aligos Therapeutics' shares. Their ALGS share price forecasts range from $2.00 to $7.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 447.9% from the stock's current price.
View analysts price targets for ALGS or view top-rated stocks among Wall Street analysts.

How have ALGS shares performed in 2023?

Aligos Therapeutics' stock was trading at $0.9529 at the beginning of the year. Since then, ALGS stock has decreased by 23.4% and is now trading at $0.73.
View the best growth stocks for 2023 here.

When is Aligos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our ALGS earnings forecast.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) issued its earnings results on Thursday, August, 3rd. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. The firm earned $6.89 million during the quarter. Aligos Therapeutics had a negative net margin of 476.77% and a negative trailing twelve-month return on equity of 86.51%.

When did Aligos Therapeutics IPO?

(ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO and Cantor was co-manager.

What is Aligos Therapeutics' stock symbol?

Aligos Therapeutics trades on the NASDAQ under the ticker symbol "ALGS."

Who are Aligos Therapeutics' major shareholders?

Aligos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (1.93%), Renaissance Technologies LLC (1.00%), Geode Capital Management LLC (0.60%) and Charles Schwab Investment Management Inc. (0.07%). Insiders that own company stock include Thomas Woiwode and Vivo Capital Fund Viii, LP.
View institutional ownership trends.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aligos Therapeutics' stock price today?

One share of ALGS stock can currently be purchased for approximately $0.73.

How much money does Aligos Therapeutics make?

Aligos Therapeutics (NASDAQ:ALGS) has a market capitalization of $31.76 million and generates $13.91 million in revenue each year. The company earns $-96,050,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis.

How can I contact Aligos Therapeutics?

The official website for the company is www.aligos.com. The company can be reached via phone at 800-466-6059 or via email at cdavis@lifesciadvisors.com.

This page (NASDAQ:ALGS) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -